Glaukos Corporation

Dose Medical Corporation

Thomas W Burns

David S Haffner

Harold Alexander Heitzmann

Gregory T Smedley

Kenneth Martin Curry

Hosheng Tu

Barbara A Niksch

Richard A Hill

Charles Raymond Kalina, Jr

Steven M Henderson

Timothy McCauley

Edward Collins

Chris Calcaterra

Morteza Gharib

Todd N Fjield

David Applegate

Richard L Lindstrom

Olav B Bergheim

Bruce Nogales

Douglas Daniel Crimaldi

Joseph P Burns

Charles Raymond Kalina

Timothy Mccauley

Kenneth M Curry

Charles Kalina

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Implants with controlled drug delivery features and methods of using same

Controlled drug delivery ocular implants and methods of using same

A gonioscopic attachment can attach to a gonioscope and can include atraumatic retention elements that are configured to engage an eye to retain the gonioscope relative to the eye. The gonioscopic attachment can be configured to position the gonioscope so that at least a portion of the concave distal surface of the gonioscopic optical element is spaced apart from the eye, and/or so that the curvature of the distal surface is angularly offset from the curvature of the eye. The gonioscope can include a fixation point configured to be visible to the subject when the gonioscope is positioned on the eye. In some embodiments, the retention elements can be incorporated directly into the gonioscope. A coupling mechanism can couple the gonioscope to a lid speculum. The gonioscope can include a light pipe, which can be configured to directly light into the eye.

Gonioscopic devices

Devices and methods for treating intraocular pressure are disclosed. The devices include shunts for draining aqueous humor from the anterior chamber to the uveoscleral outflow pathway, including the supraciliary space and the suprachoroidal space. The shunts are preferably implanted by ab interno procedures.

Uveoscleral shunt and methods for implanting same

Certain aspects relate to drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye. In several embodiments, the devices are capable of controlled release of two or more drugs, the release of each drug into a different ocular space (e.g., an ocular compartment versus an ocular fluid outflow pathway).

Drug delivery implants with bi-directional delivery capacity

An implantable intraocular physiological sensor for measuring intraocular pressure, glucose concentration in the aqueous humor, and other physiological characteristics. The implantable intraocular physiological sensor may be at least partially powered by a fuel cell, such as an electrochemical glucose fuel cell. The implantable intraocular physiological sensor may wirelessly transmit measurements to an external device. In addition, the implantable intraocular physiological sensor may incorporate aqueous drainage and/or drug delivery features.

Intraocular physiological sensor

Disclosed herein are drug delivery punctal implants and methods of using the implants for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The physical arrangement of drugs within the punctal plugs disclosed herein results, in several embodiments, in advantageous controlled delivery of one or more drugs to the eye of a patient.

Punctal implants with controlled drug delivery features and methods of using same

An ocular implant configured for implantation into the eye of a subject comprising an elongate outer shell (), an internal plug () including a hydrogel and a drug reservoir including a drug () wherein the drug is configured to pass through at least a portion of the internal plug to control elution of the drug through the outer shell. The implant is made of biodegradable materials.

Bioresorbable ocular drug delivery device

Growing community of inventors

Dana Point, CA, United States of America

Thomas W Burns